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Abstract
Background: Non-HIV/AIDS-related diseases are gaining prominence as important causes of morbidity and
mortality among people living with HIV. The purpose of this study was to characterize and compare changes over
time in mortality rates and causes of death among a population-based cohort of persons living with and without
HIV in British Columbia (BC), Canada.
Methods: We analysed data from the Comparative Outcomes And Service Utilization Trends (COAST) study; a
retrospective population-based study created via linkage between the BC Centre for Excellence in HIV/AIDS and
Population Data BC, and containing data for HIV-infected individuals and the general population of BC, respectively.
Our analysis included all known HIV-infected adults (≥ 20 years) in BC and a random 10% sample of uninfected BC
adults followed from 1996 to 2012. Deaths were identified through Population Data BC – which contains
information on all registered deaths in BC (BC Vital Statistics Agency dataset) and classified into cause of death
categories using International Classification of Diseases (ICD) 9/10 codes. Age-standardized mortality rates (ASMR)
and mortality rate ratios were calculated. Trend test were performed.
Results: 3401 (25%), and 47,647 (9%) individuals died during the 5,620,150 person-years of follow-up among 13,729
HIV-infected and 510,313 uninfected individuals, respectively. All-cause and cause-specific mortality rates were
consistently higher among HIV-infected compared to HIV-negative individuals, except for neurological disorders. All-
cause ASMR decreased from 126.75 (95% CI: 84.92-168.57) per 1000 population in 1996 to 21.29 (95% CI: 17.79-24.
79) in 2011-2012 (83% decline; p < 0.001 for trend), compared to a change from 7.97 (95% CI: 7.61-8.33) to 6.87
(95% CI: 6.70-7.04) among uninfected individuals (14% decline; p < 0.001). Mortality rates from HIV/AIDS-related
causes decreased by 94% from 103.85 per 1000 population in 1996 to 6.72 by the 2011–2012 era (p < 0.001).
Significant ASMR reductions were also observed for hepatic/liver disease and drug abuse/overdose deaths. ASMRs
for neurological disorders increased significantly over time. Non-AIDS-defining cancers are currently the leading
non-HIV/AIDS-related cause of death in both HIV-infected and uninfected individuals.
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Conclusions: Despite the significant mortality rate reductions observed among HIV-infected individuals from 1996
to 2012, they still have excess mortality risk compared to uninfected individuals. Additional efforts are needed to
promote effective risk factor management and appropriate screening measures among people living with HIV.
Keywords: Mortality, HIV infection, Age-standardized mortality rate, Mortality rate ratio, Cause of death
Background
The widespread uptake of combination antiretroviral
therapy (cART) has led to substantial reductions in
morbidity and mortality associated with HIV/AIDS
[1–3]. Over the last 20 years, cART regimens have
become, not only more effective and less toxic, but
also simpler in terms of pill burden and frequency,
thus enhancing adherence [4, 5]. This has translated
into improvement in survival among cART-treated
persons living with HIV [6]. Today in many regions,
HIV/AIDS is widely viewed as a manageable chronic
condition [7], with the life expectancy of HIV-infected
individuals receiving cART approaching that of the
general population in some settings [8–10].
Improved survival rates now observed among HIV-
infected individuals treated with cART have been ac-
companied by a gradual shift in their morbidity and
mortality patterns in some studies [11, 12]. Non-HIV-
specific diseases, including non-AIDS-defining cancers,
cardiovascular diseases (CVD), renal and liver diseases,
are becoming more prevalent with many HIV-infected
individuals now experiencing one or more of these co-
morbid conditions [11–16]. As a result, causes of death
among people living with HIV have shifted in several
important ways. In particular, deaths from these
chronic diseases and other complications typically asso-
ciated with natural aging have gained prominence as in-
dividuals are living longer on cART. It is thus
important to monitor changes in the causes of death as
this information will be useful in projecting future mor-
bidity and mortality trends. Ultimately, such knowledge
will provide guidance that may inform how risk factors
for such increasingly common adverse health outcomes
are addressed in this population.
Although decreases in all-cause mortality rates have
been well documented among HIV-infected individuals
in British Columbia (BC), Canada [1, 6, 17–21],
changes in cause-specific deaths in this population fol-
lowing cART introduction in this setting is less well
characterized. Furthermore, it is unclear how the trends
and causes of death among HIV-infected individuals in
this setting compare to that of the general uninfected
population. Given the changing pattern of causes of
death reported among HIV-infected individuals in other
settings after cART introduction [11–14], we hypothe-
sized that similar patterns may be observed among
HIV-infected BC residents. Our objective was, there-
fore, to characterize the changes in mortality rates and
causes of death over time following cART introduction
among a population-based cohort of HIV-infected indi-
viduals in BC. Secondly, we compared these patterns of
death to that observed in a population-based sample of
uninfected individuals drawn from the BC general
population over the same time period.
Methods
Study population and setting
We used data from the Comparative Outcomes And
Service Utilization Trends (COAST) study. COAST is
a large population-based retrospective cohort study
including longitudinal data of HIV-infected adults (≥
19 years) and a control group from the general popu-
lation of BC residents meeting the age criterion and
recruited into the cohort in the period between April
1, 1996 and March 31, 2013. Briefly, the COAST co-
hort was designed to characterize health outcomes
and healthcare utilization of persons living with HIV
infection since the introduction of cART and to
evaluate differences in these parameters from those
observed in the general population. COAST contains
de-identified health-related data arising from a unique
data linkage between the BC Centre for Excellence in
HIV/AIDS (BCCfE) Drug Treatment Program [22]
and Population Data BC [23]. The Drug Treatment
Program manages the province-wide antiretroviral
therapy dispensation program. It prospectively collects
demographic, immunologic, virologic, ART-use and
other clinical data on all known HIV-infected individ-
uals who have ever accessed ART, which is accessible
at no cost through the BCCfE. Population Data BC is
BC’s repository of individual-level longitudinal data
from health administrative databases [24–31]; data
that are collected by public bodies for all four million
BC residents.
The follow-up for this analysis started at cohort entry
and ended in December 31, 2012. The current analysis is
limited to COAST study participants aged 20 years or
older with at least one day of follow-up since entering
the cohort. This age criterion was necessary to facilitate
age groupings by five-year categories and thus permit
age standardization of mortality rates. The study popula-
tion comprised of two distinct cohorts distinguished by
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their HIV status. The HIV-infected cohort is comprised
of all age-eligible individuals known to be HIV-positive
during the follow-up period. HIV diagnosis was based
on the presence of at least one detectable HIV plasma
viral load, and/or an initiation of ART as indicated in the
BCCfE Drug Treatment Program registry. The HIV case
identification was supplemented through administrative
health records review of International Classification of
Diseases (ICD) – 9 and 10 codes for records with at least
one documentation of having received care for an HIV/
AIDS-related medical condition or death. The following
HIV-related ICD 9/10 codes were used: (i) ICD-9 codes
042–44, V08, 795.71, 795.8; (ii) ICD-10 codes B20-24,
R75, Z21; and (iii) ICD-10-CA codes B20-24, R75, Z21.
To avoid potential misclassification, we applied a vali-
dated HIV case-finding algorithm – an additional criteria
of ≥ 1 inpatient and/or ≥ 3 outpatient ICD-9/10 codes to
potential cases identified within administrative health re-
cords [32]. The uninfected cohort was created based on
a ten percent randomly generated sample of adult indi-
viduals from the general population of BC over the same
time frame and excludes any known HIV-infected indi-
vidual. The random sample in COAST was created by
executing a computer-generated simple random sam-
pling technique to draw a ten percent sample from a
combined pool of all distinct individuals with a Personal
Health Number (PHN) in the general population of BC
and meeting the age eligibility criterion (≥ 19 years) be-
tween April 1, 1996 and March 31, 2013. The PHN is a
unique identifier that tracks health care system encoun-
ters for all BC residents.
Outcome and definitions
Our primary outcome was death from any cause.
Deaths were identified through the BC Vital Statistics
Agency mortality dataset [31], which contains infor-
mation on all registered deaths in BC and was
accessed through a data linkage conducted by Popula-
tion Data BC. As part of the death registration in BC
as well as elsewhere in Canada, a medical certificate
of cause of death is completed by a medical examiner,
coroner or other certifier, and elicits relevant informa-
tion on the nature of the death. We classified deaths
based on the underlying cause of death information
into categories by causes using ICD-9 codes for
deaths through 1999, and ICD-10 codes for deaths
from 2000 onwards. The causes of death were
grouped into the following categories: HIV/AIDS-re-
lated, cancers, CVD, chronic respiratory diseases, drug
abuse and overdose, hepatic and liver diseases, neuro-
logic disorders, renal diseases, suicides, unintentional
injuries (including accidents), other infectious and
parasitic diseases (excluding HIV and viral hepatitis),
and ‘other causes’, which includes all causes of death
not listed in the aforementioned categories. Since
deaths from cancers such as Kaposi sarcoma, cervical
cancer and Non-Hodgkin’s lymphoma are typically
regarded as AIDS-defining; we grouped codes for
such deaths occurring within the HIV-infected cohort
under the ‘HIV/AIDS-related’ cause of death category
and excluded them from the ‘cancer’ category. Table 1
lists the ICD-9/10 codes associated with the causes of
death categories.
Table 1 Causes of death categories and the applicable ICD 9 and 10 codes
Cause of death ICD 9 code ICD 10 code
HIV/AIDS-related 042-044 B20-B24
Cancera 140-239 C00-D48
Cardiovascular diseases 410-414, 428, 430-438, 362.3 I00-I99
Chronic respiratory diseases 491, 492, 496, 493 J40-J46
Drug abuse and overdose 304, 305, E850-E858 F10-F19, F55, X40-X45, T40
Hepatic and liver diseases 070, 570-572, 275, 456, 155, 782.4 B15-B19, K70-K77
Neurologic disorders 320-327, 330-359 F03, G00-G99
Renal diseases 250.4, 403-404, 580-590, 593, 792.5, V45.1, V42.0 N00-N07, N17-N19, N25-N27
Suicides E950-E959 X60-X84, Y87.0
Unintentional injuries (including accidents)b 800-999, E800-E999 V01-Y89
Other infectious and parasitic diseasesc 001-139, 480-487 A00-B99, J10-J18
Other causes All codes not previously listed All codes not previously listed
Legend: ICD International Classification of Diseases
aSince deaths from cancers such as Kaposi sarcoma, cervical cancer and Non-Hodgkin’s lymphoma are typically regarded as AIDS-defining; we grouped codes for
such deaths occurring within the HIV-infected cohort under the ‘HIV-related’ cause of death category and excluded them from the ‘cancer’ category. The applicable
codes are: 176, 180, 200, 202 (ICD 9) and C46, C53, C82 C83 (ICD 10)
bExcludes suicides, drug abuse and overdose codes
cExcludes HIV and viral hepatitis codes
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Statistical analysis
Crude all-cause and cause-specific mortality rate per
1000 person-years (PY) were calculated from the
observed number of deaths and PYs of observation.
To account for differences in the age structure and
to permit comparability between the HIV-infected
and uninfected cohorts, we computed the age-
standardized mortality rates (ASMR) using the direct
standardization method with the 1991 Canadian cen-
sual population as the reference standard population.
The 1991 Canadian population is typically used for
the standardization of age-specific disease rates in
Canada. Additionally, we compared the ASMRs in
the cohorts per calendar interval. We divided the
observation period into 11 calendar intervals: 1996,
1997–1998, 1999–2000, 2001–2002, 2003–2004,
2005–2006, 2007–2008, 2009–2010, and 2011–2012).
Although shorter than the other calendar periods,
we elected to include 1996 (available data from April
to December) to enable us capture mortality around
the period of cART introduction. The remaining 10
calendar intervals were 2-year periods each. In sensi-
tivity analyses, we investigated trends over time in
ASMR among HIV-infected individuals according to
antiretroviral drug uptake (ever vs. never), use of
triple-drug cART at treatment initiation (yes vs.
never), both compared to uninfected individuals. We
calculated the mortality rate ratio as an estimate of
the relative risk comparing HIV-infected and unin-
fected individuals by dividing the ASMRs of HIV-
infected individuals by that of uninfected individuals.
The 95% confidence intervals (CI) for the mortality rates
and rate ratios were calculated by Normal approximation
assuming a Poisson distribution [33, 34]. Population figures
for the Canadian standard population were obtained from
Statistics Canada [35]. As a sensitivity analysis for com-
parison purposes only, we repeated the standardization of
the mortality rates using the latest available Canadian cen-
sual population (2011) [35].
Comparisons between groups were performed using
Chi-square test or Fisher exact test for categorical vari-
ables and Kruskall-Wallis test for continuous variables.
Test of trend over time were performed using Kendall
rank correlation. Statistical significance is defined at a
0.05 level. All data manipulation and statistical analyses
were performed using SAS 9.4 (Cary NC, USA) and R
Statistical Program, version 3.2.2 (Vienna, Austria).
Results
Participant characteristics
From April 1996 to December 2012, 13,729 HIV-
infected and 510,313 uninfected individuals – a com-
bined 524,042 persons – contributed a follow-up of
108,990 PYs (median: 7.22 [25th, 75th percentile: 2.96,
12.97] years per person) and 5,511,160 PYs (median:
12.70 [4.76, 16.75] years per person) of observation, re-
spectively to the analysis. The baseline characteristics of
the study participants are described in Table 2. Com-
pared to uninfected individuals, HIV-infected individuals
were more likely to be older at cohort entry (median
age: 38 vs 36 years, p < 0.001) and more likely to be male
(80% vs. 50%, p < 0.001). Roughly one-quarter of HIV-
infected individuals had no record of HIV treatment ini-
tiation. Among those who have ever received ART, ap-
proximately 37% initiated therapy with an AIDS-
defining CD4 count (< 200 cells/mm3).
Mortality during follow-up
During the approximately 17 years of observation, a
total of 3401 HIV-infected (25%) and 47,647 unin-
fected individuals (9%) died. Compared to uninfected
individuals, HIV-infected individuals were more likely
to die young (median age: 46 vs 80 years, p < 0.001),
with approximately 75% of the deaths occurring
Table 2 Characteristics of study participants
Characteristics Entire sample, n (%) Dead, n (%)
HIV+
(N = 13729)
HIV-
(N = 510313)
p-value HIV+
(N = 3401)
HIV-
(N = 47647)
p-value
Age at study entry, median (Q1, Q3) years 38 (32, 46) 36 (24, 50) <0.001 41 (34, 49) 71 (59, 78) <0.001
Age at death, median (Q1, Q3) years 46 (39, 55) 80 (69, 87) <0.001
Sex
Male 11017 (80.25) 256440 (50.25) <0.001 2716 (79.86) 24394 (51.20) <0.001
Female 2712 (19.75) 253873 (49.75) 685 (20.14) 23253 (48.80)
Follow-up time, median (Q1, Q3) years 7.22 (2.96, 12.97) 12.70 (4.76,16.75) <0.001 3.91 (1.16, 7.60) 8.42 (4.25, 12.58) <0.001
Antiretroviral therapy ever?
Yes 10165 (74.04) 2377 (69.89)
No 3564 (25.96) – 1024 (30.11) –
Legend: Q1, 25th percentile; Q3, 75th percentile
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before or at 55 years of age compared to 87 years
among uninfected individuals (Table 2). Table 3 shows
the number of deaths and crude mortality rates by
age, sex and cause of death. The proportion of deaths
among HIV-infected women (25.3%) was not signifi-
cantly different from that for infected men (24.7%) (p
= 0.529). Conversely, the proportion of deaths among
uninfected women was lower compared to uninfected
men (9.2% vs. 9.5%, p < 0.001).
Causes of death
Figures 1 and 2 show the distribution and annual
changes in the proportion of deaths across causes among
the study participants during the observation period. Al-
though HIV/AIDS-related deaths accounted for 50% of
the total deaths among HIV-infected individuals during
follow-up (Fig. 1), the proportion of deaths from HIV/
AIDS-related causes dropped from 79% in 1996 to 27%
by 2012 (p < 0.001) (Fig. 2). Overall, the top non-HIV/
AIDS-related causes of death during the study follow-up
in decreasing order are: drug abuse and overdose
(11.2%), cancers (8.5%), CVD (7.0%), and hepatic and
liver diseases (4.4%). The majority of deaths classified
under ‘other causes’ included deaths from unknown
causes and a myriad of other conditions. This cause of
death category accounted for 7.9% and 13.1% of mortal-
ity among HIV-infected and uninfected individuals
respectively.
Among HIV-infected individuals, the proportion of
deaths due to HIV/AIDS decreased significantly over
time since 1996 (p < 0.001), while those from non-HIV/
AIDS-related causes either remained stable or increased
over time (Fig. 2). In 1996, CVD and non-AIDS-defining
cancer accounted for a combined < 2% of deaths among
HIV-infected individuals compared to 29% in 2012 (p <
0.05). Non-AIDS-defining cancers which accounted for
< 1.0% of the deaths in 1996 have recently emerged to
become the leading non-HIV/AIDS-related cause of
death, accounting for 17% of all deaths among infected
individuals by 2012 (p < 0.001). Among deaths attribut-
able to non-AIDS defining cancers, lung cancer was the
most commonly observed cancer type in both HIV-
infected and uninfected individuals. In decreasing order,
this was followed by cancer of the liver, colon, pancreas,
anus, rectum, stomach and prostate among HIV-infected
individuals; and colon, breast, prostate, pancreas, blad-
der, esophagus, stomach and ovarian cancer among un-
infected individuals.
Among uninfected individuals, CVD (32%) and can-
cers (29%) were the most common accounting for over
60% of the deaths during follow-up. In terms of trend,
the proportion of deaths from CVD decreased over time
(p < 0.001), while deaths due to cancer have increased (p
= 0.02), overtaking CVD as the leading cause of death in
more recent years (Fig. 2). Consequently, in both HIV-
infected and uninfected individuals, our results demon-
strate that cancers are now the leading non-HIV/AIDS-
related cause of death. Compared to HIV-infected indi-
viduals where deaths due to drug abuse and overdose
was among the leading cause of death, this category
accounted for the least proportion of deaths among un-
infected individuals during follow-up.
Changes in age-standardized mortality rate
Figures 3 and 4 describes the changes over time in the
age-standardized all-cause and cause-specific mortality
rates, by HIV status. Among HIV-infected individuals,
the all-cause ASMR decreased from 126.75 (95% CI:
84.92-168.57) per 1000 population in 1996, to 21.29
(95% CI: 17.79-24.79) in 2011-2012 (p < 0.001 for
trend). In the uninfected population, the all-cause
ASMR changed over similar time period, from 7.97
(95% CI: 7.61-8.33) per 1000 population to 6.87 (95%
CI: 6.70-7.04), respectively (p < 0.001 for trend) (Fig. 3a).
This represents an 83% drop in all-cause mortality rate
from 1996 to 2011-2012 era among HIV-infected indi-
viduals compared to a 14% drop among uninfected in-
dividuals. The age-adjusted relative risk of death in
HIV-infected compared to uninfected individuals de-
creased from 15.90 (95% CI: 11.40-22.19) in 1996 to
3.10 (95% CI: 2.63-3.66) in the 2011–2012 era, repre-
senting a 81% reduction in the relative risk of mortality
over time. When stratified by sex, the relative risk of
death comparing infected to uninfected individuals was
similar in males and females as of 1996 (13.70 vs
13.72). By the 2011–2012 era, the relative risk of death
comparing HIV-infected and uninfected men was 2.33
(95% CI: 1.94-2.80), whereas it was 4.65 (95% CI: 3.35-
6.45) among HIV-infected compared to uninfected
women (Fig. 3b, 3c).
The ASMR from HIV/AIDS-related deaths decreased
significantly from 103.85 in 1996 to 6.72 per 1000 popu-
lation in the 2011–2012 eras (p < 0.001 for trend), repre-
senting a 94% reduction in death rate from HIV/AIDS-
related causes (Fig. 4a). Over the study’s observation
period, significant reductions in mortality rates among
HIV-infected individuals were also observed for mortal-
ity from hepatic and liver disease, as well as from drug
abuse and overdose. Although the proportion of deaths
attributable to CVD and non-AIDS-defining cancers sig-
nificantly increased over time (p < 0.05) among HIV-
infected individuals (Fig. 2a), the mortality rates from
CVD and cancer decreased over time (Fig. 4b, 4f ), albeit
not significantly (p > 0.05). There was a statistically sig-
nificant increase over time in mortality rates and propor-
tion of deaths attributable to neurological disorders
(Figs. 2a and 4j; p < 0.05). For chronic respiratory dis-
eases, renal diseases, other infectious and parasitic
Eyawo et al. BMC Infectious Diseases  (2017) 17:174 Page 5 of 15
Ta
b
le
3
Fr
eq
ue
nc
y
of
de
at
hs
an
d
cr
ud
e
m
or
ta
lit
y
ra
te
s
by
ag
e,
se
x
an
d
ca
us
es
of
de
at
h
(1
99
6-
20
12
)
H
IV
-in
fe
ct
ed
H
IV
-u
ni
nf
ec
te
d
D
ea
th
s
(%
)
p-
va
lu
e
PY
(p
er
1,
00
0)
C
M
R
pe
r
1,
00
0
PY
(9
5%
C
I)
D
ea
th
s
(%
)
p-
va
lu
e
PY
(p
er
1,
00
0)
C
M
R
pe
r
1,
00
0
PY
(9
5%
C
I)
A
ge
at
co
ho
rt
en
tr
y
(y
ea
rs
)
20
–3
4
87
3
(1
7.
44
)
<
0.
00
1
43
.3
1
20
.1
6
(1
8.
82
–2
1.
50
)
1,
92
9
(0
.7
8)
<
0.
00
1
2,
32
1.
61
0.
83
(0
.7
9–
0.
87
)
35
–4
9
1,
72
3
(2
5.
92
)
52
.7
5
32
.6
6
(3
1.
12
–3
4.
21
)
4,
73
3
(3
.5
0)
1,
71
6.
51
2.
76
(2
.6
8–
2.
84
)
50
–6
4
58
2
(3
4.
13
)
11
.2
4
51
.7
8
(4
7.
58
–5
5.
99
)
9,
63
9
(1
3.
52
)
91
6.
26
10
.5
2
(1
0.
31
–1
0.
73
)
65
+
22
3
(6
0.
43
)
1.
7
13
1.
37
(1
14
.1
3–
14
8.
62
)
31
,3
46
(5
6.
48
)
55
6.
77
56
.3
0
(5
5.
68
–5
6.
92
)
Se
x M
al
e
2,
71
6
(2
4.
65
)
0.
52
9
88
.7
6
30
.6
0
(2
9.
45
–3
1.
75
)
24
,3
94
(9
.5
1)
<
0.
00
1
2,
70
4.
30
9.
02
(8
.9
1–
9.
13
)
Fe
m
al
e
68
5
(2
5.
26
)
20
.2
3
33
.8
5
(3
1.
32
–3
6.
39
)
23
,2
53
(9
.1
6)
2,
80
6.
86
8.
28
(8
.1
8–
8.
39
)
A
RV
ev
er
?
Ye
s
2,
37
7
(2
3.
38
)
<
0.
00
1
90
.9
5
26
.1
4
(2
5.
08
–2
7.
19
)
N
o
1,
02
4
(2
8.
73
)
18
.0
4
56
.7
5
(5
3.
28
–6
0.
23
)
C
au
se
of
de
at
h
A
ll-
ca
us
e
3,
40
1
(2
4.
77
)
10
8.
99
31
.2
0
(3
0.
16
–3
2.
25
)
47
,6
47
(9
.3
4)
5,
51
1.
16
8.
65
(8
.5
7–
8.
72
)
H
IV
/A
ID
S-
re
la
te
d
1,
69
8
(1
2.
37
)
10
8.
99
15
.5
8
(1
4.
84
–1
6.
32
)
0
(0
.0
0)
5,
51
1.
16
0.
00
(0
.0
0–
0.
00
)
C
an
ce
rs
29
7
(2
.1
6)
10
8.
99
2.
72
(2
.4
2–
3.
03
)
13
,9
50
(2
.7
3)
5,
51
1.
16
2.
53
(2
.4
9–
2.
57
)
C
ar
di
ov
as
cu
la
r
di
se
as
es
23
8
(1
.7
3)
10
8.
99
2.
18
(1
.9
1–
2.
46
)
15
,2
95
(3
.0
0)
5,
51
1.
16
2.
78
(2
.7
3–
2.
82
)
C
hr
on
ic
re
sp
ira
to
ry
di
se
as
es
52
(0
.3
8)
10
8.
99
0.
48
(0
.3
5–
0.
61
)
2,
17
9
(0
.4
3)
5,
51
1.
16
0.
40
(0
.3
8–
0.
41
)
D
ru
g
ab
us
e
an
d
ov
er
do
se
38
0
(2
.7
7)
10
8.
99
3.
49
(3
.1
4–
3.
84
)
69
6
(0
.1
4)
5,
51
1.
16
0.
13
(0
.1
2–
0.
14
)
H
ep
at
ic
an
d
liv
er
di
se
as
es
15
0
(1
.0
9)
10
8.
99
1.
38
(1
.1
6–
1.
60
)
75
5
(0
.1
5)
5,
51
1.
16
0.
14
(0
.1
3–
0.
15
)
N
eu
ro
lo
gi
c
di
so
rd
er
s
19
(0
.1
4)
10
8.
99
0.
17
(0
.1
0–
0.
25
)
3,
27
3
(0
.6
4)
5,
51
1.
16
0.
59
(0
.5
7–
0.
61
)
Re
na
ld
is
ea
se
s
21
(0
.1
5)
10
8.
99
0.
19
(0
.1
1–
0.
28
)
74
6
(0
.1
5)
5,
51
1.
16
0.
14
(0
.1
3–
0.
15
)
Su
ic
id
es
88
(0
.6
4)
10
8.
99
0.
81
(0
.6
4–
0.
98
)
71
2
(0
.1
4)
5,
51
1.
16
0.
13
(0
.1
2–
0.
14
)
U
ni
nt
en
tio
na
li
nj
ur
ie
s
87
(0
.6
3)
10
8.
99
0.
80
(0
.6
3–
0.
97
)
1,
79
2
(0
.3
5)
5,
51
1.
16
0.
33
(0
.3
1–
0.
34
)
O
th
er
in
fe
ct
io
us
an
d
pa
ra
si
tic
di
se
as
es
10
1
(0
.7
4)
10
8.
99
0.
93
(0
.7
5–
1.
11
)
1,
99
8
(0
.3
9)
5,
51
1.
16
0.
36
(0
.3
5–
0.
38
)
O
th
er
ca
us
es
27
0
(1
.9
7)
10
8.
99
2.
48
(2
.1
8–
2.
77
)
6,
25
1
(1
.2
2)
5,
51
1.
16
1.
13
(1
.1
1–
1.
16
)
Le
ge
nd
:A
RV
A
nt
ire
tr
ov
ira
l(
dr
ug
),
CI
C
on
fid
en
ce
In
te
rv
al
s,
CM
R
C
ru
de
m
or
ta
lit
y
ra
te
,P
Y
Pe
rs
on
-y
ea
rs
Eyawo et al. BMC Infectious Diseases  (2017) 17:174 Page 6 of 15
Fig. 1 (See legend on next page.)
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(See figure on previous page.)
Fig. 1 Overall distribution of the proportion of deaths by causes and by HIV status in British Columbia, during 1996-2012. Legend: *, Values are in
the format ‘median age (25th percentile-75th percentile)’ years; Note: The ‘cancer’ category in Fig. 1a excludes deaths attributable to Kaposi
sarcoma, cervical cancer and Non-Hodgkin’s lymphoma, as these have been accounted for within HIV/AIDS-related deaths. a HIV-infected,
b HIV-uninfected
Fig. 2 Annual changes in the proportion of deaths by causes and by HIV status in British Columbia, during 1996–2012. Legend: CVD, Cardiovascular
diseases; *, Each bar in the figure represents a one-year period beginning in 1996 (except for the first bar – 1996 –, which is nine months long); Note:
The ‘cancer’ category in Fig. 2a excludes deaths attributable to Kaposi sarcoma, cervical cancer and Non-Hodgkin’s lymphoma, as these have been
accounted for within HIV/AIDS-related deaths. a HIV-infrcted, b HIV-uninfected
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Fig. 3 Changes over time in all-cause age-standardized mortality rates, overall and by HIV status and sex in British Columbia, during 1996–2012.
Legend: CI, Confidence interval; MRR, Mortality rate ratio. a Overall, b Male-only, c Female only
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Fig. 4 (See legend on next page.)
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diseases deaths, mortality rate increases were observed
but this was not significant.
Among uninfected individuals, statistically significant
mortality rate reductions were observed over time for
deaths attributable to CVD, cancers, chronic respiratory
diseases, suicides, unintentional injuries and other infec-
tious and parasitic diseases; however mortality rates at-
tributable to neurologic disorders increased significantly
over time.
Sensitivity analyses
Although we observed slightly higher ASMRs (data
not shown) when we standardized rates using a 2011
Canadian censual population compared to the main
analyses that used a 1991 censual population, the
overall trends remained unchanged. The slight in-
crease in mortality rates is likely because the 2011
censual population has a higher proportion of individ-
uals in older age groups than the 1991 population. In
separate analyses stratified by antiretroviral therapy
uptake (ever vs. never) and initiation of therapy with
triple-drug cART (yes vs. never on therapy), we ob-
served significant mortality rate reductions over time
across all groups (Figs. 5 and 6). During the analytic
period, individuals who were never on ART had mor-
tality rates ranging from 1.4 to almost 5 times higher
than among those ever on ART or those initiating
treatment with triple-drug cART. Of note, 92% of in-
dividuals ever on ART in this study initiated therapy
on a triple-drug cART.
Discussion
Since cART introduction in 1996, this is the first
population-based study in Canada to characterize
changes in mortality and causes of death among persons
living with HIV infection as compared to uninfected in-
dividuals from the same geographical and health care
setting. Compared to uninfected individuals, our result
demonstrates that the causes of death among HIV-
infected individuals in BC have changed dramatically
over time. We observed significant mortality rate reduc-
tions in all-cause, HIV/AIDS-related, drug abuse and
overdose, and liver disease mortality among people living
with HIV in the period from 1996 to 2012. Despite the
remarkable decline in mortality from HIV-related
causes, HIV/AIDS is still the leading cause of death
Fig. 5 Trend in age-standardized mortality rate, by HIV and antiretroviral therapy uptake status (ever vs. never) in British Columbia, during 1996–2012.
Legend: ARV, Antiretroviral (drug); CI, Confidence interval
(See figure on previous page.)
Fig. 4 Changes over time in cause-specific age-standardized mortality rates, by HIV status in British Columbia, during 1996–2012. Legend: The
‘cancer’ mortality line graph for HIV-infected individuals (Fig. 4f, red line) excludes deaths attributable to Kaposi sarcoma, cervical cancer and
Non-Hodgkin’s lymphoma, as these have been accounted for within HIV/AIDS-related deaths. a HIV/AIDS related, b cardiovascular diseases,
c Hepatic and liver diseases, d Renal diseases, e Chronic respiratory diseases, f Cancers, g Suicides, h Drug abuse and overdose, i unintentional injuries,
j Neurologic disorders, k Other infectious and parasitic diseases, l Other causes
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among HIV-infected individuals and the relative risk of
death remains in excess of that for uninfected individ-
uals. Relative to other causes of death, the proportion of
total mortality attributable to non-AIDS-defining cancer
and CVD has increased among HIV-infected individuals
since cART introduction, however, this did not necessar-
ily translate into a trend of increasing mortality rates
from these causes; a finding that may be likely due to
the overall increased survival in the population. In both
HIV-infected and uninfected individuals, we observed
significant increases over time in mortality rates from
neurologic disorders.
The overall proportion of deaths due to HIV/AIDS-re-
lated causes in our study (50.2%) was comparable to
those reported from Spain (40.4%) [36], Italy (41.4%)
[16], Denmark (44.4%) [37], England and Wales (46.0%)
[38], France (47.3%) [39], USA (51.4%) [15] and from
multinational cohort collaborations such as Antiretro-
viral Therapy Cohort Collaboration (49.6%) [14], but
higher than that reported in the Data collection on Ad-
verse events of Anti-HIV Drugs [D:A:D] study (28.7%)
[40]. While our overall findings are broadly consistent
with the mortality declines and cause of death trends
presented in previous studies of HIV-infected individuals
from other settings [13–16, 38, 40, 41]; variations in the
range of such estimates may exist across studies and are
likely due to heterogeneity in the population (e.g., by
age, sex, CD4 levels, cART history, underlying clinical
characteristics, ethnicity), differences in the observation
period, or the coding scheme for causes of death
categories. In sensitivity analysis stratified by ART up-
take (ever vs. never), we observed a better mortality
prognosis among those who had ever been treated with
ART, thus demonstrating the benefit associated with
ART. This is supported by a recent BC study among
HIV-infected individuals receiving cART since 2001
which demonstrated that cART initiation was independ-
ently associated with reduced mortality [21].
The current study reflects major changes since the
introduction of cART in terms of non-HIV/AIDS-related
causes; in 1996, only 21% of the deaths among HIV-
infected individuals were attributable, as compared to
73% by 2012. Our results confirm two recent reports
suggesting that non-AIDS-defining cancers are currently
the leading non-HIV/AIDS-related cause of death
among HIV-infected individuals [40, 42]. Similarly, we
observed that cancers have also recently overtaken CVD
to become the principal cause of death among the unin-
fected population. Like the D:A:D study [40] but unlike
a report from the HIV Outpatient Study [15], we ob-
served a statistically significant mortality rate decrease
from hepatic and liver disease deaths. Contrary to a find-
ing among HIV-infected hemophiliacs in Canada [43],
liver disease is an important cause of death especially
among individuals co-infected with HIV and hepatitis C
virus [44], although not the main non-HIV/AIDS-related
cause of death in the current study. The observed in-
crease in mortality rates attributable to neurologic disor-
ders is likely a reflection of the increased longevity in
both populations.
Fig. 6 Trend in age-standardized mortality rate, by HIV and highly active antiretroviral therapy (HAART) status at treatment initiation (yes vs. never)
in British Columbia, during 1996-2012. Legend: ARV, Antiretroviral (drug); CI, Confidence interval; HAART, Highly active antiretroviral therapy
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Our results indicating that HIV-infected individuals
continue to have a mortality risk ratio that is decreasing
as time passes but remains approximately three times
more than in uninfected individuals as of 2011-2012 is
supported by comparable findings from other studies
that have compared mortality rates among persons with
and without HIV infection [37, 45]. We suspect the con-
tinuing high relative risk of death among HIV-infected,
compared to uninfected individuals may in part be ex-
plained by the higher prevalence of behavioral risk fac-
tors such as smoking, alcohol abuse and other lifestyle
factors that are more common among HIV-infected in-
dividuals and predisposes them to higher mortality risk
compared to uninfected individuals.
Readers should interpret our findings in light of the
potential strengths and limitations of the study. The
HIV-infected cohort includes the vast majority of all
known HIV-infected adults in BC, irrespective of
whether they had ever received cART. Despite universal
access to HIV treatment in BC, approximately 25% of
HIV-infected individuals had no record of HIV treat-
ment initiation during this study (1996 to 2012). Re-
assuringly, the rates have declined substantially with the
implementation of the Treatment as Prevention strategy
in BC [46–48], as in a 2008 study we found that 40% of
those who died from HIV did not access treatment [49].
Our uninfected cohort includes randomly sampled BC
residents who accessed the same universal health care
system as the HIV-infected participants, thus minimizing
potential selection bias that may arise from using an ex-
ternal comparison group. Unlike most clinic-based co-
horts [11, 13, 16, 36, 39, 40, 50], the relatively large,
linked and population-based nature of the COAST study
is unique to BC and has allowed us to ascertain mortal-
ity and cause of death information for all study partici-
pants through the same source – the BC Vital Statistics
Agency -[31], which is the provincial office that collects
vital statistic records in BC. However, since this dataset
does not capture deaths to BC residents that occur out-
of-province, such deaths were unaccounted for in our
analyses. While we suspect this number is likely small, it
also will have affected the HIV-infected and uninfected
cohorts equally. Finally, our cause of death assessment is
limited by the accuracy of the ICD-9/10 coding used for
attribution of the underlying cause of death; and the
study as a whole, by unmeasured confounding due to its
observational nature.
Conclusion
To sum up, our results suggest that significant improve-
ments have been made in reducing mortality over time
from HIV/AIDS-related and several non-HIV/AIDS-re-
lated causes of death among people living with HIV.
Despite this progress, HIV-infected individuals still have
excess mortality risk compared to their uninfected
counterparts. Additional efforts are needed to promote
effective risk factor management and appropriate screen-
ing measures among people living with HIV. Ongoing
monitoring of mortality trends by causes will be import-
ant and will provide the necessary data to enable us opti-
mally target our efforts at the conditions that influence
morbidity and mortality outcomes. Ultimately, in both
HIV-infected and uninfected populations, the manage-
ment of cancers and CVD as well as their known risk
factors will be key in improving overall survival
outcomes.
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